Inhibitory effect of levamisole and adriamycin on rat mammary cancer induced by 7,12-dimethylbenz(a)anthracene

Tominaga, Takeshi; Kitamura, Masatsugu; Saito, Taeko; Itoh, Ichiji

doi:10.1016/0014-2964(80)90060-2

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When levamisole, which is a synthetic phenyl imidazole‐thiazole, became available for therapeutic trial as an immune modulating agent, it showed promise as an adjunct to chemotherapy 4–8. On the strength of these observations, Davis et al9 studied 5‐FU with and without levamisole in patients with residual, recurrent, or metastatic colorectal carcinoma with unmeasurable disease.…”

mentioning

confidence: 99%

Comparison of 5-fluorouracil alone, 5-fluorouracil with levamisole, and 5-fluorouracil with hepatic irradiation in the treatment of patients with residual, nonmeasurable, intra-abdominal metastasis after undergoing resection for colorectal carcinoma

Witte

Cnaan

Mansour

et al. 2001

Cancer

View full text Add to dashboard Cite

BACKGROUND The authors conducted a randomized Phase III trial of three treatment regimens for patients with residual, nonmeasurable, intra‐abdominal metastatic disease after undergoing resection for primary colorectal carcinoma. METHODS To be eligible for this study, patients had to be both free of other malignancies and capable of starting their therapy within 3–6 weeks after surgery. They were required to have an Eastern Cooperative Oncology Group performance status < 3; to be chemotherapy, radiation, and immunotherapy naïve; to have adequate bone marrow, renal, and hepatic function; and to provide written, informed consent. The patients were divided into two cohorts: patients with no demonstrable hepatic metastasis (Group A) and patients with hepatic metastasis (Group B). RESULTS The 229 patients in Group A were randomized to receive either 5‐fluorouracil (5‐FU) (n = 116 patients) or 5‐FU with levamisole (n = 113 patients). The median survival (15.4 months and 15.3 months, respectively, for Groups A and B) was virtually identical. The two groups also were similar in terms of time to treatment progression, which was 7.9 months for group that received 5‐FU alone 7.7 months for the group that received levamisole with 5‐FU. The 168 patients in Group B with hepatic metastasis underwent a three‐way randomization: 5‐FU alone (n = 60 patients), 5‐FU with levamisole (n = 54 patients), and 5‐FU with hepatic irradiation (n = 54 patients). The median overall survival for the three treatment arms were similar, with 17.3 months for the group that received 5‐FU alone, 16 months for the group that received 5‐FU with levamisole, and 14.4 months for the group that received hepatic irradiation in addition to 5‐FU: The time to treatment failure was 6.7 months, 6.8 months, and 8.3 months, respectively, for the three groups. The toxicity experienced by patients was as expected with the regimens, and no differences were observed between any of the treatment groups. The primary toxicities were hematologic and gastrointestinal. There was one treatment‐related death due to adult respiratory distress syndrome, which occurred on the first day of the fourth cycle of 5‐FU and levamisole. Other Grade 4 toxicities included nine patients with Grade 4 leukopenia, one patient with Grade 4 sepsis, and one patient with Grade 4 gastrointestinal toxicity, including blood loss and diarrhea. CONCLUSIONS This study showed no treatment advantage for any of the combined modalities over 5‐FU alone in this group of patients with intra‐abdominal, nonmeasurable disease. Cancer 2001;91:1020–8. © 2001 American Cancer Society.

show abstract

mentioning

confidence: 99%

Comparison of 5-fluorouracil alone, 5-fluorouracil with levamisole, and 5-fluorouracil with hepatic irradiation in the treatment of patients with residual, nonmeasurable, intra-abdominal metastasis after undergoing resection for colorectal carcinoma

Witte

Cnaan

Mansour

et al. 2001

Cancer

View full text Add to dashboard Cite

show abstract

“…Some investigators have reported the inhibitory effects of immunopotentiators on mammary car cinogenesis in animals [7,8]. We have previously shown that the occurrence of 7,12-dimethylbenz-[a]anthracene (DMBA)-induced rat mammary tumors decreased and the period required to develop the first tumor in each rat was prolonged by the administra tion of immunopotentiators [9].…”

Section: Introductionmentioning

confidence: 99%

Effects of OK-432 (Picibanil) on Estrogen Receptor Levels and Tamoxifen Treatment in 7,12-Dimethylbenz[a]anthracene-Induced Rat Mammary Cancers

Iino

Ogawa²,

Yoshida³

et al. 1990

Oncology

View full text Add to dashboard Cite

The effects of OK-432 (Picibanil) on estrogen receptor (ER) levels and subsequent tamoxifen (TAM) treatment were examined in 189 female Sprague-Dawley rats with 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary cancers. When OK-432 was administered (0.1 KE/kg i.p. once weekly) for 12 weeks to the rats after DMBA, the average ER level of the TAM-responsive tumors in the OK-432-treated group was significantly higher than that in the control group. The antitumor effect of TAM was significantly greater in the OK-432-treated group. When OK-432 was administered to rats with established DMBA tumors, the average ER levels did not change significantly after 2 or 4 weeks of treatment. ER levels in the control group (no treatment) fell significantly after 2 or 4 weeks. These results suggest that hormone dependence of DMBA-induced rat mammary cancers may be maintained or augmented by the administration of OK-432.

show abstract

Inhibitory effect of levamisole and adriamycin on rat mammary cancer induced by 7,12-dimethylbenz(a)anthracene

Cited by 2 publications

References 5 publications

Comparison of 5-fluorouracil alone, 5-fluorouracil with levamisole, and 5-fluorouracil with hepatic irradiation in the treatment of patients with residual, nonmeasurable, intra-abdominal metastasis after undergoing resection for colorectal carcinoma

Comparison of 5-fluorouracil alone, 5-fluorouracil with levamisole, and 5-fluorouracil with hepatic irradiation in the treatment of patients with residual, nonmeasurable, intra-abdominal metastasis after undergoing resection for colorectal carcinoma

Effects of OK-432 (Picibanil) on Estrogen Receptor Levels and Tamoxifen Treatment in 7,12-Dimethylbenz[a]anthracene-Induced Rat Mammary Cancers

Contact Info

Product

Resources

About